Serplulimab with carboplatin and etoposide can be used, within its marketing authorisation, as an option for untreated extensive-stage small-cell lung cancer in adults. Serplulimab with carboplatin and etoposide can only be used if the company provides it according to the commercial arrangement.
Serplulimab with carboplatin and etoposide must be funded in the NHS in England for the condition and population in the recommendation, if it is considered the most suitable treatment option. Serplulimab with carboplatin and etoposide must be funded in England within 90 days of final publication of this guidance.
There is enough evidence to show that serplulimab with carboplatin and etoposide provides benefits and value for money, so it can be used routinely across the NHS in this population.
NICE has produced tools and resources to support the implementation of this guidance.
Usual treatment for most people with untreated extensive-stage small-cell lung cancer is atezolizumab plus carboplatin and etoposide.
Clinical trial evidence shows that serplulimab plus carboplatin and etoposide increases how long people have before their cancer gets worse and how long people live compared with placebo plus carboplatin and etoposide.
Serplulimab plus carboplatin and etoposide has not been directly compared in a clinical trial with atezolizumab plus carboplatin and etoposide. The results of an indirect comparison are uncertain because of the methods used.
There are also some uncertainties in the economic model. But when considering the condition's severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates are within the threshold that NICE considers an acceptable use of NHS resources. So, serplulimab plus carboplatin and etoposide can be used.